专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20160303133A1 TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS 审中-公开
标题翻译：治疗胃肠病和其他疾病
公开(公告)号：US20160303133A1
公开(公告)日：2016-10-20
申请号：US14782304
申请日：2014-04-04
申请人： NUMEDII, INC.
发明人： Joel DUDLEY , Carol CHRISTOPHER , Pankaj PASRICHA
IPC分类号： A61K31/5355 , A61K31/165 , A61K9/00 , A61K31/166 , A61K31/145 , A61K31/138 , A61K31/167
CPC分类号： A61K31/5355 , A61K9/0014 , A61K9/0031 , A61K9/0048 , A61K9/0053 , A61K9/0056 , A61K9/0078 , A61K9/06 , A61K9/4866 , A61K31/138 , A61K31/145 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/5377 , A61K31/573 , A61K45/06
摘要： Provided herein are methods and compositions for treating gastrointestinal disorders using beta blockers. Compositions comprising Beta blockers such as Timolol and Nadolol are used to treat diseases including ulcerative colitis, IBD and Crohn's disease. The Compositions are administered orally or rectally, at doses that provide a peak plasma concentration of less than 10 ng/ml.
摘要翻译：本文提供了使用β受体阻滞剂治疗胃肠道疾病的方法和组合物。包含β阻滞剂如噻吗洛尔和纳多洛尔的组合物用于治疗包括溃疡性结肠炎，IBD和克罗恩病的疾病。组合物以口服或直肠给药，剂量达到峰值血浆浓度小于10ng / ml。

52. 发明申请

US20160271188A1 PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND METHODS OF USE THEREOF FOR TREATMENT OF GASTROINTESTINAL DISORDERS 审中-公开
标题翻译：生物和预后组合物及其用于治疗胃肠疾病的方法
公开(公告)号：US20160271188A1
公开(公告)日：2016-09-22
申请号：US14952894
申请日：2015-11-25
申请人： Epiva Biosciences, Inc.
发明人： David Berry , Noubar B. Afeyan , Johanne Kaplan , Shaila Rahman
IPC分类号： A61K35/74 , A61K31/7004 , A61K9/19 , A61K31/7016 , A61K35/742 , A61K35/744 , A61K9/00
CPC分类号： A61K35/74 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K31/7004 , A61K31/7016 , A61K31/715 , A61K35/39 , A61K35/741 , A61K35/742 , A61K35/744 , A61K35/745 , A61K35/747 , A61K38/46 , A61K2035/115 , Y02A50/401 , Y02A50/414 , Y02A50/473
摘要： Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent disorders of the local or systemic microbiome, e.g., gastrointestinal disorders, in a subject are also provided.
摘要翻译：本文描述了含有非致病微生物实体（例如细菌实体）的益生菌组合物。益生菌组合物可以任选地含有或与一种或多种益生元结合使用。还提供了益生菌组合物用于治疗或预防受试者中局部或全身微生物组织疾病例如胃肠道疾病的用途。

53. 发明授权

US09433662B2 Fusion proteins and methods for treating HIV infection and AIDS related symptoms 有权
标题翻译：用于治疗HIV感染和AIDS相关症状的融合蛋白和方法
公开(公告)号：US09433662B2
公开(公告)日：2016-09-06
申请号：US14988341
申请日：2016-01-05
申请人： TIANJIN XIJI BIOTECHNOLOGY CO., LTD.
发明人： Pingfan Rao , Shutao Liu
IPC分类号： C12N9/02 , A61K9/00 , A61K38/44 , A61K38/45 , A61K38/08 , C07K7/06 , A61K31/7072 , A61K31/506 , A61K31/536 , C12N9/10
CPC分类号： A61K38/446 , A61K9/0031 , A61K9/006 , A61K31/506 , A61K31/536 , A61K31/7072 , A61K38/08 , A61K38/45 , A61K45/06 , A61K47/67 , B82Y5/00 , C07K7/06 , C07K14/4711 , C07K2319/03 , C07K2319/036 , C12N9/0089 , C12N9/1088 , C12Y115/01001 , C12Y205/01018
摘要： Pharmaceutical compositions and methods for using a fusion protein having a superoxide dismutase and a transit peptide are described. Pharmaceutical compositions and methods for using the fusion protein in combination with other antiretroviral agents for treating patients with AIDS or HTV infection are also described.
摘要翻译：描述了使用具有超氧化物歧化酶和转运肽的融合蛋白的药物组合物和方法。还描述了将融合蛋白与其他抗逆转录病毒剂组合用于治疗AIDS或HTV感染患者的药物组合物和方法。

54. 发明申请

US20160243147A1 TOPICAL ANTIFUNGAL COMPOSITIONS AND METHODS OF USE THEREOF 审中-公开
标题翻译：局部抗真菌组合物及其使用方法
公开(公告)号：US20160243147A1
公开(公告)日：2016-08-25
申请号：US15027481
申请日：2014-10-06
申请人： REVOLUTION PHARMA LLC
发明人： Craig W. CARVER
IPC分类号： A61K31/7048 , A61K31/4174 , A61L15/44 , A61K31/137 , A61K9/06 , A61K31/496 , A61K9/00 , A61K31/4178
CPC分类号： A61K31/7048 , A61K9/0014 , A61K9/0031 , A61K9/0034 , A61K9/06 , A61K31/137 , A61K31/4174 , A61K31/4178 , A61K31/496 , A61L15/44 , A61L2300/404 , A61K2300/00
摘要： Described herein are topical anti-fungal pastes and methods that treat fungal infections of the skin, reduce the severity and duration of symptoms of fungal infections of the skin, and prevent recurrence of fungal infections. The topical pastes described herein are composed of an admixture of one or more antifungal agents, excipient inert powder, and a pharmaceutically acceptable topical carrier. The compositions and methods described herein minimize fungal resistance and maximize the number of targeted fungal strains. Additionally, the compounds and methods do not suppress the body's immune system either locally or systemically, thus allowing for a faster restoration of normal skin flora. The compositions and methods described herein are particularly suitable for use in infants and children as well as in immunocompromised individuals, diabetics, and the obese.
摘要翻译：本文描述的是治疗皮肤的真菌感染的局部抗真菌糊剂和方法，降低皮肤真菌感染症状的严重性和持续时间，并防止真菌感染的复发。本文所述的局部糊剂由一种或多种抗真菌剂，赋形剂惰性粉末和药学上可接受的局部载体的混合物组成。本文描述的组合物和方法使真菌抗性最小化并使目标真菌菌株的数目最大化。此外，化合物和方法不会局部或全身地抑制身体的免疫系统，从而允许更快恢复正常的皮肤菌群。本文所述的组合物和方法特别适用于婴儿和儿童以及免疫受损个体，糖尿病患者和肥胖者。

55. 发明申请

US20160235792A1 PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND METHODS OF USE THEREOF FOR TREATMENT AND PREVENTION OF GRAFT VERSUS HOST DISEASE 审中-公开
公开(公告)号：US20160235792A1
公开(公告)日：2016-08-18
申请号：US14952892
申请日：2015-11-25
申请人： Epiva Biosciences, Inc.
发明人： David Berry , Noubar B. Afeyan , Johanne Kaplan , Neal Gordon , Shaila Rahman
IPC分类号： A61K35/747 , A61K35/744 , A61K35/745 , A61K35/742
CPC分类号： A61K35/74 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K31/7004 , A61K31/7016 , A61K31/715 , A61K35/39 , A61K35/741 , A61K35/742 , A61K35/744 , A61K35/745 , A61K35/747 , A61K38/46 , A61K2035/115 , Y02A50/401 , Y02A50/414 , Y02A50/473
摘要： Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial or fungal entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent transplant disorders, e.g., graft-versus-host disease (GVHD), in a subject are also provided.

56. 发明授权

US09409986B2 IL-1 binding proteins 有权
标题翻译： IL-1结合蛋白
公开(公告)号：US09409986B2
公开(公告)日：2016-08-09
申请号：US14133380
申请日：2013-12-18
申请人： AbbVie, Inc.
发明人： Chengbin Wu , Dominic J. Ambrosi , Chung-ming Hsieh , Tariq Ghayur
IPC分类号： A61K38/00 , C07K14/545 , C07K16/24 , A61K39/395 , A61K47/48 , A61K45/06 , G01N33/68 , A61K9/00
CPC分类号： C07K16/245 , A61K9/0014 , A61K9/0019 , A61K9/0031 , A61K9/0034 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/007 , A61K9/0085 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K47/6879 , C07K14/545 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92 , G01N33/6869 , G01N2333/545 , G01N2800/00 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/412 , Y02A50/463 , Y02A50/478 , Y02A50/481
摘要： Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.
摘要翻译：描述了结合IL-1α和IL-1β的蛋白质及其在用于治疗，预防和诊断IL-1相关病症并用于检测细胞，组织，样品中的IL-1α和IL-1β的组合物和方法中的用途，和组合物。

57. 发明申请

US20160206711A1 Treatment of Mammalian Physiological Reaction of IgE Antibodies Present in Said Mammal Upon Contact with the Corresponding Antigen 有权
标题翻译：治疗存在于所述哺乳动物中与相应抗原接触的IgE抗体的哺乳动物生理反应
公开(公告)号：US20160206711A1
公开(公告)日：2016-07-21
申请号：US15083540
申请日：2016-03-29
申请人： Ira Sanders
发明人： Ira Sanders
IPC分类号： A61K38/48 , A61K9/00
CPC分类号： A61K38/4893 , A61K9/0019 , A61K9/0031 , A61K9/0043 , A61K9/0046 , A61K9/007 , A61K9/0073 , A61K38/00 , A61K38/164 , A61K48/00 , A61K2039/543 , C12N15/74 , C12Y304/24069 , Y02A50/469
摘要： A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.
摘要翻译：公开了一种通过向所述哺乳动物施用治疗有效量的来源于梭菌的神经毒素（CnT）来阻断或减少哺乳动物体内存在于所述哺乳动物中的IgE抗体与相应抗原接触相互作用的方法 sp。

58. 发明申请

US20160184266A9 COMPOSITION AND METHOD FOR TREATMENT OF DIABETES 审中-公开
标题翻译：用于治疗糖尿病的组合物和方法
公开(公告)号：US20160184266A9
公开(公告)日：2016-06-30
申请号：US14113650
申请日：2012-05-02
申请人： Jerzy Ryszard Szewczyk
发明人： Jerzy Ryszard Szewczyk
IPC分类号： A61K31/40 , A61K31/19 , A61K31/197
CPC分类号： A61K31/40 , A61K9/0031 , A61K9/02 , A61K9/2846 , A61K31/19 , A61K31/197 , A61K31/198 , A61K31/4015 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a method of treating diabetes type II by delivery of butyric acid, bile acid, long chain fatty acid or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a DPP-IV inhibitor such as vildagliptin.
摘要翻译：本发明涉及通过旁路上消化道将丁酸，胆汁酸，长链脂肪酸或谷氨酰胺递送至结肠来治疗II型糖尿病的方法。组合物通过相同或不同的给药途径与DPP-IV抑制剂如维格列汀组合。

59. 发明申请

US20160175405A1 FUSION PROTEINS AND METHODS FOR TREATING HIV INFECTION AND AIDS RELATED SYMPTOMS 有权
标题翻译：融合蛋白和治疗艾滋病毒感染和艾滋病相关症状的方法
公开(公告)号：US20160175405A1
公开(公告)日：2016-06-23
申请号：US14988341
申请日：2016-01-05
申请人： TIANJIN XIJI BIOTECHNOLOGY CO., LTD.
发明人： Pingfan Rao , Shutao Liu
IPC分类号： A61K38/44 , C07K7/06 , A61K38/08 , C12N9/10 , A61K31/7072 , A61K31/506 , A61K31/536 , C12N9/02 , A61K38/45 , A61K9/00
CPC分类号： A61K38/446 , A61K9/0031 , A61K9/006 , A61K31/506 , A61K31/536 , A61K31/7072 , A61K38/08 , A61K38/45 , A61K45/06 , A61K47/67 , B82Y5/00 , C07K7/06 , C07K14/4711 , C07K2319/03 , C07K2319/036 , C12N9/0089 , C12N9/1088 , C12Y115/01001 , C12Y205/01018
摘要： Pharmaceutical compositions and methods for using a fusion protein having a superoxide dismutase and a transit peptide are described. Pharmaceutical compositions and methods for using the fusion protein in combination with other antiretroviral agents for treating patients with AIDS or HTV infection are also described.
摘要翻译：描述了使用具有超氧化物歧化酶和转运肽的融合蛋白的药物组合物和方法。还描述了将融合蛋白与其他抗逆转录病毒剂组合用于治疗AIDS或HTV感染患者的药物组合物和方法。

60. 发明申请

US20160175310A1 BOOSTING THE EFFECT OF METHOTREXATE THROUGH THE COMBINED USE WITH LIPOPHILIC STATINS 审中-公开
标题翻译：通过组合使用的脂肪组织来促进甲硝唑的作用
公开(公告)号：US20160175310A1
公开(公告)日：2016-06-23
申请号：US14909210
申请日：2014-08-01
申请人： DALANA3, S.L.
发明人： Jose Manuel Garcia Castellano
IPC分类号： A61K31/519 , A61K31/366
CPC分类号： A61K31/519 , A61K9/0014 , A61K9/0019 , A61K9/0031 , A61K9/0053 , A61K31/366 , A61K31/40 , A61K31/404 , A61K31/517 , A61K45/06 , A61K2300/00
摘要： The invention relates to the use of an inhibitor of the dihydrofolate reductase enzyme selected from the group that consists of methotrexate, trimetrexate and pemetrexed; or a pharmaceutically acceptable salt thereof, for the preparation of a drug for the treatment or prevention of recurrences of a disease selected from the group that consists of cancer, psoriasis, psoriatic arthritis, juvenile polyarticular arthritis, rheumatoid arthritis, Crohn's disease, polymyositis, dermatomyositis and sarcoidosis, wherein said treatment or prevention includes administering to a patient, simultaneously, separately or sequentially, a lipophilic statin and the inhibitor of the dihydrofolate reductase enzyme. The invention also relates to a pharmaceutical composition which includes the inhibitor of the dihydrofolate reductase enzyme and the lipophilic statin together with pharmaceutically acceptable carriers and/or vehicles.
摘要翻译：本发明涉及二氢叶酸还原酶抑制剂的使用，其选自甲氨蝶呤，三甲氧嘧啶和培美曲塞组成的组; 或其药学上可接受的盐，用于制备用于治疗或预防由癌症，牛皮癣，银屑病关节炎，幼年型关节炎，类风湿性关节炎，克罗恩病，多发性肌炎，皮肌炎组成的组的疾病复发的药物的药物和结节病，其中所述治疗或预防包括向患者同时分别或依次施用亲脂性他汀和二氢叶酸还原酶的抑制剂。本发明还涉及药物组合物，其包含二氢叶酸还原酶和亲脂性他汀类药物与药学上可接受的载体和/或载体的抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式